BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Table 2

Ongoing clinical trials evaluating potential drug targets of BRCA1.

Drug class	Compound	Phase	Clinical trial number	Study population
PARP inhibitors	MK4827	Phase I	NCT00749502	EOC
	AG014699	Phase II	NCT00664781	Advanced EOC
	KU-0059436 (AZD2281)	Phase I	NCT00647062	EOC with or without BRCA1 mutation
	KU-0059436 (AZD2281) in combination with doxorubicin	Phase II	NCT00628251	BRCA1/2 mutation positive EOC
	ABT-888 in combination with bevacizumab, carboplatin, paclitaxel	Phase I	NCT00989651	EOC
	ABT-888 in combination with temozolomide	Phase I	NCT00526617	EOC
	KU-0059436 (AZD2281)	Phase II	NCT00679783	EOC with or without BRCA1 mutation
	KU-0059436 (AZD2281)	Phase II	NCT00753545	Platinum sensitive serous EOC
	BSI-201	Phase II	NCT00677079	Advanced EOC
	ABT-888 in combination with topotecan	Phase I/II	NCT01012817	EOC
HDAC inhibitors	SAHA (vorinostat) in combination with paclitaxel, carboplatin	Phase I/II	NCT00772798	EOC
	SAHA (vorinostat) in combination with carboplatin, gemcitabine	Phase I/II	NCT00910000	EOC
	Hydralazine and magnesium valproate	Phase III	NCT00533299	Advanced EOC
CHK inhibitors	UCN-01 in combination with irinotecan	Phase I	NCT00031681	Metastatic EOC
Proteasome inhibitors	PS-341(bortezomib) in combination vandetanib	Phase I/II	NCT00923247	EOC
	PS-341	Phase II	NCT00023712	Platinum-sensitive EOC